Figures computed from official regulatory filings — .
Analysttarget 107.74 USD (+8%) · consensus 3.5/5 · 3 buy · 7 hold · 0 sell
Ownershipinsiders 1.73% · institutions 116.76% · short 7.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Lantheus Holdings, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
8 buys385 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Marshall Robert J. Jr. | Other | $72.8K | SEC |
| Brown Kimberly | Other | $46.7K | SEC |
| Dinkelborg Ludger | Other | $255.9K | SEC |
| Heino Mary Anne | Other | $118.6K | SEC |
| Ber Gerard | Other | $36.8K | SEC |
| Baylor-Henry Minnie | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ber Gerard | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| EASTLAND JULIA MARIE | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Maeusli Heinz Christophtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thrall James H | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Morrow Phuong Khanh | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| McHugh Julie | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pruden Gary J | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LENO SAM R | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Niedzwiecki Daniel | Other | $160.2K | SEC |
| Brown Kimberly | Other | $10.1K | SEC |
| Niedzwiecki Daniel | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Dinkelborg Ludger | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Niedzwiecki Daniel | Other | $97.9K | SEC |
| Marshall Robert J. Jr. | Other | $90.2K | SEC |
| Marshall Robert J. Jr. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Brown Kimberly | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Morgan Amanda Michelle | Other | $45.4K | SEC |
| Morgan Amanda Michelle | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Niedzwiecki Daniel | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |